NASDAQ: $RGC Investors have faced challenging and
Post# of 37118
Times of turbulence affect all stocks, large and small. It can be particularly challenging for pre-revenue microcap stocks, where the volatility is often magnified by small changes in perception, whether driven by news or technical trading signals.
We first wrote on Regencell Bioscience (NASDAQ:RGC) and its preliminary trials for ASD/ADHD, in November 2021. At that time, the stock was trading around $20/share. It rose to $40 by mid-February 2022, before dropping back to the low 20s in early April.https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html